Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,…